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Abstract
Background: Little is known concerning risk factors for herpes zoster in the general population. We hypothesised
that inhaled corticosteroids (ICS) are a risk factor for herpes zoster especially among users of inhibitors of
cytochrome P450 enzymes involved in their metabolism.
Methods: We identified a cohort of adult users of respiratory medications in the General Practice Research
Database and carried out a nested case control analysis of inhaled corticosteroid use among 8900 new cases of
herpes zoster and 88032 controls matching on age and calendar time.
Results: The adjusted odds ratio for the relationship between current use of ICS and the occurrence of herpes
zoster was 1.00 (95% confidence interval (CI), 0.94-1.07). There was no increase in risk of herpes zoster even at
higher ICS doses; odds ratio 1.05 (95% CI, 0.96-1.14). Among subjects with concomitant prescriptions for an ICS and
an inhibitor of cytochrome P450 3A4, the point estimate for the association between herpes zoster and the use of
higher doses of inhaled corticosteroids was 1.23 (95% CI, 0.81-1.88).
Conclusions: The use of inhaled corticosteroids, even at high doses and in conjunction with inhibitors of their
metabolism, was not a significant risk factor for the occurrence of herpes zoster in adults.
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Background
Inhaled corticosteroids (ICS) are being increasingly used
in the treatment of patients with asthma and with
chronic obstructive pulmonary disease (COPD). These
medications are systemically absorbed and may have
systemic adverse effects such as cataracts and fractures
[1,2]. The use of high doses of ICS has recently been
found to increase the risk of severe pneumonia in
patients with COPD [3,4]. Information on other infec-
tious complications of ICS therapy is scant but low
doses of oral corticosteroids with similar systemic
potency have been linked to an excess of serious infec-
tions [5]. Moreover, ICS are metabolised via the cyto-
chrome P450 (CYP) system which is involved in
biotransformation of the vast majority of all drugs cur-
rently available [6,7]. Therefore patients often find
themselves taking several medications competing for the
same enzymes required for their biotransformation into
inactive compounds which can then be excreted.
Herpes zoster (shingles) results from reactivation of
latent varicella zoster virus. The lifetime risk of zoster is
estimated to be 10-30% and incidence increases mark-
edly with age, affecting up to 50% of people who live up
to 85 years [8,9]. The most common complication of
zoster is chronic pain due to post herpetic neuralgia.
The risk of this complication can be reduced by the
prompt administration of anti-viral agents; however,
20% of people older than 50 years who receive treat-
ment still experience pain six months after rash onset
[10]. Factors responsible for the majority of cases occur-
ring in apparently well individuals have not been identi-
fied [8].
Given the impairment in cell mediated immunity asso-
ciated with the use of corticosteroids and the systemic
activity of ICS, especially at higher doses, a study of the
link between use of ICS and herpes zoster appears war-
ranted. We therefore undertook a study in a large pri-
mary care clinical database in order to assess the risk of
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population of adults and to evaluate whether this risk is
increased by the concomitant use of ICS and drugs
which inhibit CYP3A4, the enzyme responsible for the
hepatic inactivation of corticosteroids.
Methods
The study cohort was identified from the population-
based General Practice Research Database (GPRD),
which has been described in detail. It is one of the
world’s largest computerised databases with longitudinal
data, including the demographic characteristics, medical
diagnoses, laboratory test data and prescription informa-
tion for about 6.4 million patients from over 400 Gen-
eral practices in the U.K [11-13]. Subjects were eligible
if they were registered as permanent in an up-to-stan-
dard practice for at least one year without a diagnosis of
herpes and without a prescription for a bronchodilator,
a cromolyn, a leukotriene antagonist or an inhaled corti-
costeroid; in this way, we attempted to include mostly
new users of respiratory medications. Subjects then
entered the cohort on the day of their third prescription
on at least two different dates of a respiratory drug
within one year. All cohort members were followed up
from cohort entry until a diagnosis compatible with
herpes zoster was recorded, death, exit from the practice
or December 30
th, 2007, whichever occurred first. We
identified new cases of herpes zoster occurring during
follow-up using diagnostic codes previously identified
for a study of the risks of NSAIDs for severe skin and
soft tissue complications of varicella infections [14]. We
carried out a nested case-control analysis where each
case was matched to up to 10 controls selected from the
cohort, based on age (within 12 months), and presence
in the cohort in the year and month (± 30 days) of the
diagnosis of herpes zoster in the case.
Inhaled corticosteroid (ICS) exposure included pre-
scriptions for beclometasone, budesonide, triamcinolone,
fluticasone and flunisolide, whether dispensed alone or
in a combination inhaler with an inhaled b agonist. The
estimation of equivalencies were chosen on the basis of
relative topical potency and what experts consider to be
comparable doses according to the NAEPP expert panel
report (EPR-2), figures 3-5b and 3-5c [15] and the Cana-
dian asthma consensus statement, Table 8 [16]. Accord-
ingly, the equivalent doses for inhaled corticosteroids
are beclometasone 100 mcg, budesonide 80 mcg, triam-
cinolone 200 mcg, fluticasone 50 mcg and flunisolide
200 mcg. All doses were converted to fluticasone
equivalents and categorised according to defined daily
doses [17] of the most recent prescription in the appro-
priate time window as high (fluticasone 500 mcg per
day or more), moderate (fluticasone 200-499 mcg per
day), and low (less than 200 mcg per day). We also
defined a very high dose category as fluticasone 1000
mcg per day or more. Current use of inhaled corticos-
teroids was defined as a prescription for an ICS given to
the patient within the 60 days before the occurrence of
zoster (or the matching index date for controls). Cumu-
lative dose of ICS in the prior year was also calculated
and expressed as fluticasone equivalents. Since there are
differences in the systemic potencies of the different ICS
[18], we also looked at risk by type of ICS.
Statistical analysis was done using conditional logistic
regression to calculate the odds ratio of zoster in rela-
tion to the use of ICS up to the index date, that is the
date the diagnoses of herpes was diagnosed in the case.
Crude odds ratios, already adjusted for age and calendar
time by matching, were also adjusted for gender and
smoking status and for the prescription of oral, nasal
and injectable corticosteroids in the same time windows
as exposure to ICS. Severity of respiratory disease was
accounted for by adjusting for each medication class,
including antibiotics, prescribed in the prior year, as
well as the occurrence of a hospitalisation with a
respiratory diagnosis in the prior year. To adjust for co-
morbidity, the presence of cardiovascular disease includ-
ing hypertension and diabetes were identified by the
prescription of cardiovascular and diabetes drugs respec-
tively. We also adjusted for the recording of a diagnosis
of cancer (excluding non-melanoma skin cancer) in the
prior year as well as a prior history of varicella or zoster.
To examine whether a decrease in metabolism of
inhaled corticosteroids might increase the risk of herpes
zoster, we looked at the relationship with use of inhaled
corticosteroids among subjects with concomitant pre-
scriptions of any of the following inhibitors of CYP3A4:
amiodarone, aprepipant, clarithromycin, ciprofloxacin,
delavirdine, diltiazem, erythromycin, fluoxetine, imatinib,
indinavir, isoniazid, itraconazole, ketoconazole, nefazo-
done, nelfinavir, norfloxacin, ritonavir, saquinavir,
tamoxifen, verapamil, and voricovazole.
The study has received ethical approval from The
Medicines and Healthcare Products Regulatory Agency
(MHRA), protocol 07_047R.
Results
The cohort consisted of 178,704 adults of whom 57.7%
had a diagnosis of asthma recorded, 13.5% a diagnosis
of COPD and 23.1% a diagnosis of wheezing noted after
cohort entry. The average age at cohort entry was 52.8
years (SD 19.3) and 42.5% of cohort members were
men. There were 8,900 cases of herpes zoster identified
during cohort follow-up. These were matched to 88,032
controls by age and date of diagnosis. Descriptive infor-
mation on diagnoses and medication use reported in the
prior year is provided in Table 1. Cases of herpes zoster
were more commonly women. Monitoring by peak flow
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tory specialists was uncommon. The most apparent dif-
ferences were the greater use of oral corticosteroids and
antibiotics in cases than in controls.
The adjusted odds ratio for the relationship between
current use of ICS and the occurrence of herpes zoster
was 1.00 (95% confidence interval (CI), 0.94-1.07). In
this same analysis, the risk associated with the prescrip-
tion of oral corticosteroids was significantly elevated;
adjusted odds ratio 1.23 (95% CI, 1.15-1.31). As shown
in Table 2, there is no increase in risk of herpes zoster
at higher ICS doses; adjusted odds ratio 1.05 (95% CI,
0.96-1.14). Even when looking at very high doses equiva-
lent to fluticasone 1000 mcg per day or more, there was
no significant risk demonstrable; adjusted odds ratio
0.93 (95% CI, 0.78-1.12). We looked at whether cumula-
tive dose of inhaled corticosteroids over the prior 12
months was associated with risk of zoster. The risk did
not increase with increasing exposure such that even
among subjects prescribed more than 4 inhalers of high
dose inhaled corticosteroid (fluticasone 500 mcg per day
or more) in the past year the adjusted odds ratio was
0.97 (95% CI, 0.89-1.07).
We examined the effect of different corticosteroids
and were unable to identify an excess risk with any par-
ticular ICS; adjusted odds ratio for fluticasone 1.03 (95%
CI, 0.93-1.15). Table 3 shows the risk of herpes zoster
among subjects with concomitant prescriptions for an
ICS and an inhibitor of CYP3A4. The number of cases
was substantially less (n = 475) due to the inability to
find appropriate matched controls for most cases. While
the point estimate for the odds ratio was elevated at
1.24 among those prescribed higher doses of inhaled
corticosteroids, the confidence interval was wide (95%
CI, 0.81-1.90) and included no association.
Discussion
While our results strongly suggest that inhaled corticos-
teroids do not represent a significant risk for zoster in
adults, this lack of an association might possibly to due
to methodological problems such as insufficient sample
size and misclassification of outcome or of exposure.
Insufficient sample size is unlikely to explain the overall
results given the 8900 cases of zoster and the frequent
prescribing of inhaled corticosteroids in our cohort. As
for the quality of the information on diagnoses and pre-
scription in the GPRD, this has been repeatedly demon-
strated [11,19]. We cannot, however, rule out the
possibility that the lack of an effect results from patients
not taking the inhaled corticosteroids they were pre-
scribed. An association between use of inhaled corticos-
teroids and risk of herpes zoster might be masked if
physicians were less likely to prescribe inhaled corticos-
teroids in patients thought to at increased risk of zoster.
This is unlikely to explain the lack of an association
found here since we were able to adjust for known and
suspected risk factors for zoster present in the year
prior to diagnosis and that information on these risk
factors and on prescribed medication was gathered pro-
spectively. Furthermore we included mostly new users
of respiratory medications such that subjects at highest
risk of the outcome had not ceased exposure to inhaled
corticosteroids [20]. Subjects prescribed inhaled corti-
costeroids, especially at higher doses are also likely to be
older, sicker and to have been prescribed oral corticos-
teroids and therefore at greater risk of zoster [21]. This
explains the slight increases seen in the crude odds
ratios of the association of higher doses of inhaled corti-
costeroids with zoster. The lower odds ratios after
adjustment strongly suggest that there is no additional
risk associated with the use of inhaled corticosteroids.
The 60 day time window for current exposure is based
Table 1 History and Medication Use in the Prior Year
among Zoster Cases and Controls
Cases Controls
History* (n = 8900) (n = 88032)
Age mean (SD) 54.7 (24.4) 54.4 (24.2)
Gender, male % 38.6 44.4
Asthma % 32.5 31.5
Asthma exacerbation % 3.3 2.6
COPD % 10.1 9.6
COPD exacerbation % 2.2 1.7
Wheezing % 5.5 4.9
Other lung disease % 2.8 2.2
Peak Flow test% 30.1 29.2
Referral to respiratory physician % 0.5 0.5
History of varicella % 0.2 0.2
History of zoster % 0.4 0.1
Respiratory Hospitalisation % 1.2 0.9
Cancer % 1.9 1.2
Medications prescribed*
Inhaled Corticosteroids (ICS) % 47.3 46.6
Beclometasone % 36.3 36.4
Budesonide % 6.9 6.8
Fluticasone % 4.1 3.4
Other ICS % 0.1 0.1
ICS+ Long acting b-agonist % 11.3 9.9
Long acting b-agonist % 7.7 7.2
Short acting b-agonist % 61 60.1
Other respiratory drugs % 27.7 24.6
Nasal corticosteroids % 10.8 10
Injection corticosteroids % 1.9 1.6
Oral corticosteroids % 19.9 15.2
Antibiotics % 61.5 52.6
Anti-diabetics drugs % 5.6 5
Cardiac drugs % 46.4 42.9
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risk for this infectious complication to be maximal for
ICS prescribed within the prior 60 days and for the effect
to wane quickly thereafter [4]. Even if ICS are most com-
monly dispensed as a 30 day supply, based on our prior
experience, there is sufficient variability in prescribing
and in patient compliance with the prescribed dose to
expect that current exposure should include a 30 day
period after the nominal termination of a dispensed pre-
scription. To examine the possibility that an association
may have been missed due to inappropriate timing of the
exposure window and the possibility that excess risk may
be associated with cumulative rather than recent expo-
s u r e ,w ea l s oe x a m i n e dt h er i sk of zoster in relation to
the total dose of inhaled corticosteroids prescribed in the
past year. Again, no risk was apparent in the highest dose
category (fluticasone 500 mcg per day or more) even
among patients making regular use of these medications
(more than four prescriptions in the past year). It must
be noted that the analysis examining the risk of zoster
among concomitant users of inhaled corticosteroids and
inhibitors of pertinent cytochrome oxidase enzymes had
limited power since matched controls could only be iden-
tified for 475 cases of zoster. Thus, we cannot rule out an
excess risk of zoster in patients making concomitant use
of ICS and potent inhibitors of CYP3A4 such as ritonavir.
Yang and colleagues recently reported an excess in risk of
herpes zoster in patients with COPD [22]. Such patients
comprise approximately 10% of our study population.
They also found a greater risk if the COPD patients had
received oral corticosteroids while the risk was not signif-
icantly elevated in COPD patients receiving inhaled corti-
costeroids as compared to those not prescribed any
corticosteroids.
Conclusion
We identified 8900 cases of herpes zoster in a large
cohort of patients followed by general practitioners in
the U.K. After adjusting for known (age, gender, oral
corticosteroids, malignancy [9] and potential risk factors
such as type of chronic respiratory disease [21,22] and
diabetes [23], there was no excess in risk of herpes zos-
ter among patients prescribed inhaled corticosteroids,
even at high doses, nor among patients prescribed con-
comitant inhibitors of corticosteroid metabolism which
would be expected to increase the systemic adverse
effects of inhaled corticosteroids.
Factors responsible for the more frequent cases of zos-
ter occurring in individuals without marked impairment
in their immune status are unknown. Such lack of
knowledge has been called surprising given the fre-
quency of the problem and its significant morbidity [8].
We had hypothesized that use of inhaled corticosteroids,
especially at higher doses and in combination with inhi-
bitors of pertinent cytochrome oxidase enzymes, might
be a risk for zoster; however, we were unable to find
a n ye v i d e n c eo fa ne x c e s sr i s ko fz o s t e rw i t ht h eu s eo f
inhaled corticosteroids.
Table 2 Inhaled Corticosteroid (ICS) use and risk of Herpes Zoster in 8900 cases and 88032 controls
Cases Controls Crude odds ratio Adjusted odds ratio* (95% CI†)
ICS
no use% 45.4 46.9 1.00 Reference
high dose% 13.1 11.6 1.19 1.05 (0.96-1.14)
medium dose% 14.3 14.7 1.01 0.97 (0.90-1.05)
low dose% 2.9 2.9 1.05 1.02 (0.89-1.17)
*Adjusted for gender, smoking status, all the variables in Table 1, as well as past use of ICS.
†CI: confidence interval
Table 3 Inhaled Corticosteroids (ICS) and the Risk of Herpes Zoster Among Cases and Controls Treated with Inhibitors
of Cytochrome Oxidase P450 3A4*
Cases (n = 475) Controls (n = 760) Crude Odds Ratio Adjusted Odds Ratio† (95% CI ‡)
ICS
no use% 35.6 36.1 1.0 reference
high dose% 24.4 20.8 1.13 1.24 (0.81-1.90)
medium dose% 16.8 18.2 0.95 0.94 (0.63-1.41)
low dose% 2.5 3.3 0.75 0.66 (0.29-1.48)
*see list of inhibitors of cytochrome P450 3A4 in methods.
†Adjusted for gender, smoking status, all the variables in Table 1, as well as past use of ICS.
‡CI: confidence interval
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